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Abstract A partial p opioid receptor gene was isolated from a human genomic library using a mouse 6 opioid receptor cDNA as a probe. Using 
information from this genomic lone and the published human p receptor, MORl , a cDNA was isolated from SK-N-SH mRNA that codes for a 
variant of the MORl mRNA, MORlA. The presence of MORIA is also shown in human brain using RT-PCR. MORlA differs from MORl in 
that the 3’ terminal intron has not been removed. An in-frame termination codon is found four amino acids after the 5’ consensus plice site, making 
MORIA eight amino acids shorter than MORI. Both receptors how similar ligand binding and coupling to CAMP in CHO-Kl cells. The C-terminal 
differences between MORl and MORlA could have effects on receptor coupling or receptor transport and localization. 
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1. Introduction 
The opioid receptors are G-protein coupled receptors that 
play a major role in pain management. However, they are also 
associated with many side effects, such as constipation, respira- 
tory depression, dependence and tolerance [l]. Pharmacologist 
have identified 3 basic types of opioid receptors, p, K and 6, as 
well as subtypes of these receptors [2-51. It has been suggested 
that many of the opioid side-effects will be associated with a 
particular receptor subtype and that the development of spe- 
cific agonists and antagonists would eliminate many of these 
side-effects [6]. The recent cloning of the mouse S opioid recep- 
tor, DORl [7,8], which has lead to the cloning of other opioid 
receptors [g-17], may help bring this idea to fruition. However, 
as yet no receptor subtype cDNAs of p, K or 6 have been 
cloned. While looking for receptor subtypes, we discovered a 
splice variant of the human fl opioid receptor. The human 
p opioid receptor, MORl, and this variant, MORlA, have 
similar ligand aflinity. The variant is also negatively coupled to 
CAMP in CHO-Kl cells, and mRNA coding for the variant can 
be found in human brain. It is possible that the changes in the 
variants C-terminus may modulate the receptor’s G-protein 
coupling or affect its cellular distribution. 
2. Materials and methods 
2.1. Cloning oj the human opioid receptor variants 
DORl [7,8] was cloned and used to screen a human genomic library 
(Stratagene) as described in detail by Mansson [17]. Two clones, OR7 
and OR4, were identified with homology to rat ,u opioid receptor 
(rMOR1) [9,10]. 
The human p opioid receptor cDNA variants were cloned from 
SK-N-SH mRNA using RT-PCR. Reverse transcription was per- 
formed on 0.5 pg of mRNA using 0.1 PM of either a specific primer 
(RTMl, GCCTCCTACACATTCTTGAAG) corresponding to the 
3’ non-coding region of the published human MORl [15], or a specific 
*Corresponding author. Fax: (1) (908) 7716488. 
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primer to the new variant (RTMZ, AGAACCAGAGCAAGACTGG- 
C) corresponding to 3’ non-coding sequences in the genomic p opioid 
receptor clone, OR7 (i.e. proposed intron 3 region of hMOR). The 
products from the RT reactions were purified using Glassmax spin 
columns (Gibco/BRL) and used as substrates for PCR reactions. A 
1447 bp MORl clone was PCR amplified using the forward primer 
(MFl, CTAGGTACCGCAGAGGAGAATGTCAGAT) with an 
added k$nl site and a reverse primer (MRl, GATCTCGAGCTAA- 
GCTTGGTGAAGGTCGG) with an added fiol site based on the 
published 5’ and 3’ non-coding sequence of the human MORl [15]. A 
1485 bp p receptor variant, MORIA, was cloned using the same for- 
ward primer used to clone MORl and a reverse primer (MR2, CTA- 
GGTACCAAGCTTCCCTCCATICTCATCCTC) specific for the 
3’ non-coding sequence in the genomic p opioid receptor clone, OR7 
(i.e. the proposed intron 3 region of hMOR1) plus an added Kpnl site. 
All PCR reactions were performed using 1 PM primers, 1110 of the 
purified cDNA, and 1 U Taq Polymerase (Perkin-Elmer) in the supplied 
buffer for 35 cycles of 1 min at 94”C, 1 min at 56”C, and 2 min at 72°C 
followed by a 10 min 72’C extension. The PCR products, representing 
the published human MORl and a variant of the human MORl, were 
cloned into SK plasmids (Stratagene), sequenced and the inserts sub- 
cloned into the expression vector pcDNA3 (Invitrogen) to create 
pcMOR1 and pcMOR1A. The above PCR reactions were also done 
with mRNA from SK-N-SH and human brain in which the forward 
primers were replaced with the primer (MF2, CAATGTCTG- 
CAACTGGATCC) which is specilic to TM #4 of both MORl and 
MORlA cDNAs. 
2.2. PCR analysis and Southern blots 
20 ~1 of the 50 ~1 PCR reactions were analyzed by electrophoresis 
on a 1% agarose gel, and stained with ethidium bromide. The gels 
were blotted onto nylon filters and hybridized in 50% formamide at 
42°C to either a [‘*pldCTP nick-translated pchMor1 insert or to the 
oligo (GTACGCAGTCTCTAGAATTAGGTATATCTACTGGGG- 
ATGACAT), which is specific to the 3’ non-coding region of MORIA, 
and was [32P]dATP poly(A) tailed with terminal transferase. The filters 
were washed twice in 2 x SSC, 0.1% SDS, and twice in 0.5 x SSC, 0.1% 
SDS, all at 42’C. In addition, the oligo-probed filter was washed once 
in 0.25 x SSC, 0.1% SDS at 42’C and the MORl-probed filter was 
washed in 0.2 x SSC, 0.1% SDS at 55°C. The filters then were exposed 
to X-ray film with intensifying screens. 
2.3. Expression and characterization f hMOR1 and hMORZA 
Stable clones expressing the MORl and the MORlA receptors were 
made by transfecting 70% confluent CHO-Kl cells in a 35 mm dish with 
8 pug of either pcMOR1 or pcMORlA and 8 ,ul of lipofectAMINE 
(GibcolBRL) for 5 h in 1 ml of serum free Ham’s F-12 media. 1 ml of 
media with 20% fetal calf serum (FCS) was added, which was replaced 
with 10% serum after 24 h from the start of transfection. After 48 h the 
cells were split 1 to 30 into ten 100 cm dishes with media containing 
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10% FCS and 1 mg/ml Geneticin (Gibco/BRL). After 14 days colonies 
were picked and grown to confluency in 24 well microtiter dishes. 
Receptor expression was con6rmed using rH$liprenorphine in a whole 
cell binding assay [21], and a high expressing cell line was selected for 
further studies. For binding studies, cells were grown to confluency, and 
membranes were prepared according to Raynor et al. [18]. For compet- 
itive binding studies, cell membranes (40-60 pg) were incubated with 
[‘Hjdiprenorphine (0.4 nM) in the presence of a competing ligand for 
60 min at 25°C in a final volume of 500 ~1. Saturation binding studies 
were done as described using increasing concentrations of [Hkiiprenor- 
phine or rHlDAMGG. Non-specitlc binding was defined as the 
amount of bindine in the nresence of 10 uM levornhanol (= 5-101 of 
the total binding).-All assays were performed in triplicate using 50 mM 
Tris, pH 7.4, and analyzed using the program LIGAND [22]. 
For CAMP analysis, cells were grown to confluency in 12 well costar 
plates, treated with 1 mM 3-isobutyl-1-methylxanthine and 1 mM fors- 
kolin for 30 min with or without the agonist DAMGG (0.5 mM), 
dissolved in 0.5 ml 1 M HCl, lyophilixed and analyzed for CAMP using 
an Amersham kit (TRK432). 
3. Results and discussion 
Screening of a human genomic library at low stringency with 
a 1 kb DORl cDNA fragment was used to isolate two clones, 
OR7 and 0R4. Subsequent restriction mapping and Southern 
blotting revealed that OR7 and OR4 represented the same gene. 
DNA sequencing of subclones hybridizing to the DORl probe 
showed the greatest homology to rat p opioid receptor 
(rMOR1) [9,10]. Six transmembrane regions (TM) correspond- 
ing to TM #2-7 of rMOR1 were identified. The 5’ end of the 
gene containing TM #l either is not present in these clones or 
does not hybridize to the DORl probe under the conditions 
used. A termination codon was identified 52 amino acids fol- 
lowing TM #7, which is similar to the termination codon found 
60 amino acids following TM #7 in rMOR1 [9,10]. We demon- 
started the presence of mRNA by RT-PCR, amplifying frag- 
ments of the receptor from SK-N-SH messenger RNA with 
primers RTM2, MR2 and MF2, which are based on the 
3’ non-coding and TM #4 regions of the OR7 clone (Fig. 1, 
lane3). Recently, Wang et al. [15] published a human p cDNA 
sequence which is identical to exon regions of OR7 except for 
the 3’ end. Part of this discrepancy was explained by an intronl 
exon boundary that Wang et al. [ 151 identified 12 amino acids 
from the 3’ end of hMOR1. However, because we could PCR- 
amplify fragments of MOR from SK-N-SH mRNA containing 
a different 3’ end than reported for MORl, we speculated that 
we may have identified a splice variant of the human MORl 
receptor which we call MORlA. 
The presence of full-length mRNAs for human MORl [15] 
and for the p variant, MORlA, derived from sequence infor- 
mation of OR7, MORlA, was demonstrated in SK-N-SH 
mRNA using RT/PCR. Both the RT and 3’ PCR primers were 
specific to either MORl or MORlA. MORl’s RT primer 
(RTMl), 5’ PCR primer (MFl), and 3’ PCR primer (MRl) 
were designed from the published sequence [15]. The MORlA 
variant’s RT primer (RTM2), and 3’ PCR primer (MR2), were 
designed using information obtained from sequencing of the 
OR7 clone. The 5’ PCR primer (MFl) was the same one used 
to clone MORl. A shorter PCR product could also be ampli- 
fied in the reactions by substituting MFl with a new 5’ PCR 
primer (MF2), the sequence of which is common to TM #4 of 
OR7 and the published MORl sequence [15]. The results of the 
RT-PCR on the SK-N-SH message is shown in Fig. 1. Lane 1 
shows the presence of a 679 PCR product containing the 3’-half 
MORl MORlA 
Ml 234 
Fig. 1. Agarose gel demonstrating the presence of MORl and MORlA 
mRNA in SK-N-SH cells. Ethidium bromide-stained agarose gel of the 
RT-PCR products from SK-N-SH mRNA. Lanes 1 and 2 used RT and 
3’ PCR primers specific to MORl and lanes 3 and 4 used RT and 
3’ PCR primers specific to MORlA. Lanes 1 and 3 used a 5’ PCR 
primer common to TM #4 of MORl and MORl A. Lanes 2 and 4 used 
a 5’ PCR mimer to the 5’ non-codina &on of MORl to vield complete 
cDNA cdding regions. Lane M co&i& PXl74IHaeIII and U&d111 
markers (GibcolBRL). 
of the MORl cDNA, and lane 2 shows the presence of a 1447 
bp PCR product containing a full-length MORl cDNA. The 
presence of MORlA mRNA in SK-N-SH cells is confirmed in 
lanes 3 and 4 of Fig. 1. Lane 3 shows the presence of a 7 17 PCR 
product containing the 3’-half of the MORlA cDNA, and lane 
2 shows the presence of a 1485 bp PCR product containing a 
full-length MORlA cDNA. The difference in staining intensity 
suggests that MORlA mRNA is about 5-fold less abundant 
than MORl mRNA in SK-N-SH cells. The full-length cDNAs 
of MORl and MORlA were gel-purified, cloned, and se- 
quenced. The MORl clone contained a reading frame coding 
for the complete 400 amino acid MORl receptor [ 151, and the 
MORlA clone contained a reading frame coding for a 392 
amino acid protein that differs from MORl only at its 3’ end. 
It is unlikely that the MORlA product is PCR amplification 
of unspliced heterogenous nuclear RNA, since PCR amplifica- 
tion of the 1485 bp MORlA cDNA requires that intron 1 and 
2 be removed. Larger PCR products, or no products at all, 
would have been the result if these introns were present. The 
PCR primers for the short product span intron 2 (0.8 kb). If 
intron 2 were not removed, some 1.5 kb product would have 
been observed during the PCR. Instead only the 717 base pair 
product is observed. 
Fig. 2 shows the differences in the 3’ coding regions of MORl 
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H Q L E N L E A E T A P L P 
MORl CAT CAG CTA GAA AAT CTG GAA GCA GAA ACT GCT CCG TTG CCC TAA CAG 
CGC AGT CTC TAG ATT TAG GTA 
HQVRSL- 
t 
Concensus 5’ Splice Site 
Fig. 2. Comparison of the DNA and amino acid sequences at the 3’ end of MORl and MORlA. Stop codons are underlined, and a consensus 
5’ splice site is boxed in MORl A. All the 5’ coding sequence not shown is identical between receptors. The nucleotide sequence has been submitted 
to Genbank (#U12569). 
and MORlA. The nucleotides coding for the first 388 amino 
acids of MORlA are identical to MORl*. MORl continues for 
an additional 12 amino acids before terminating, and MORlA 
continues for four amino acids before terminating. A consensus 
5’ splice site can be seen in MORlA’s DNA sequence (and in 
the OR7 clone) at the position that MORl and MORlA’s 
sequences differ, suggesting that only in MORl has this splice 
site been used. A similar event in the somatostatin gene (i.e. 
alternative use of a 3’ splice site) leads to two functional soma- 
tostatin receptors, SSTR2A and SSTR2B [18,19]. 
Both MORl and MORlA mRNAs are present in human 
brain, although MORlA mRNA appears to be less abundant 
in human brain than in SK-N-SH cells. Fig. 3A shows the 
ethidium bromide-stained RT-PCR products from human 
brain mRNA using RT and 3’ PCR primers specific to either 
MORl or MORlA and a common 5’ PCR primer to TM #4. 
The MORlA PCR product is 717 bp and the MORl PCR 
product is 679 bp. MORlA appears to be at least lo-fold less 
abundant than MORI in human brain mRNA as compared to 
about 5-fold in SK-N-SH mRNA. To further demonstrate the 
specificity of the PCR reactions, the gel was Southern-blotted 
and probed using a 43 nucleotide probe specific to MORlA’s 
3’ end. Fig. 3B shows that only the MORlA PCR products 
hybridize to the MORlA specific probe. Furthermore, probing 
the blot with a probe containing the common regions of MORl 
and MORlA demonstrates that the PCR products are of the 
,u opioid gene (Fig. 3C). The PCR product of MORl and 
*Nucleotide differences between MORl [15] and MORlA are noted in
Genbaak U12569. 
kd 
A B 
MORl MORlA MORl 
MORlA containing the complete coding region could also be 
PCR amplified from human brain mRNA, and showed the 
same hybridization specificity as the shorter product shown in 
Fig. 3 (data not shown). 
The results of receptor binding experiments performed using 
membranes isolated from CHO-Kl cells stably expressing 
MORl or MORlA are shown in Table 1. Data for the satura- 
tion binding of diprenorphine to MORl and MORlA are 
shown in Fig. 4. MORl and MORlA have similar affinities to 
diprenorphine (both & = 0.13 nM) and to DAMGO (& = 0.26 
and 0.15 nM, respectively). Neither EC or S selective ligands at 
high concentrations (>l PM) displace diprenorphine from the 
MORl or MORlA, but the ,u specific ligand DAMGO does 
effectively displace diprenorphine. 
MORl and MORlA were analyzed for their ability to couple 
to CAMP (Table 2). Treatment of CHO-Kl cells stably express- 
ing MORl or MORlA with 0.5 mM DAMGO and forskolin 
caused a 32% (MORl) and 39% (MORlA) reduction in CAMP 
compared to cells treated with only forskolin, indicating that, 
like other opioid receptors, both MORl and MORlA are func- 
tionally coupled to CAMP in CHO-Kl cells. 
We re-examined the genomic clone OR7 for the presence of 
the 3’ terminus of MORl using a probe specific to MORl’s 
3’ non-coding region (data not shown), but could not identify 
a hybridizing fragment. Since OR7 is approximately 15 kb, the 
human MOR gene is large. This also is true of the human 
K receptor (>15 kb) which contains a large first intron, and a 
3.5 kb second intron [16]. Our data indicates that the MORl 
gene’s first intron between TM #l and TM #2 is at least 8 kb, that 
the second intron between TM #Q and TM #5 is 0.8 kb and that 
C 
MORlA MORl MORlA 
Fig. 3. Identification of MORl and MORlA mRNA in human brain. (A) Ethidium bromide-stained agarose gels of the RT-PCR products from 
human brain. The RT and 3’ PCR primers were specific to either MORl or MORlA. The same 5’ PCR primer to TM #4 was used for both PCR 
reactions. The gel was Southern-blotted and probed with an oligomer 43 nucleotide long that is specific to MORlA (B) or the pchMOR1 insert that 
is common to both MORl and MORlA receptors (C). 
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Diprenorphine @Ml 
Fig. 4. Saturation binding of [3H]diprenorphine using membranes 
from CHO-Kl cell stably expressing the cDNA for MORl (B,,,, = 760 
fmol/mg) or MORlA (B,, = 520 fmol/mg). Data are expressed as 
f S.E.M. 
the third intron is greater that 3 kb. It is this third intron that 
is alternatively spliced to produce MORl and MORlA vari- 
ants. 
There appears to be at least two possible explanations of the 
MORlA clone. First, it may be a true variant with ligand 
affinities similar or identical to MORl [ 151 and similar CAMP 
coupling. We have identified this transcripts in the mRNA of 
both SK-N-SH cells and in human brain mRNA via RT-PCR. 
Precedence for alternative splicing of a 3’ intron comes from 
the alternative splicing of the somatostatin receptor gene to 
form the SSTR2A and SSTR2B variants [ 18,191. These somato- 
statin receptor variants have similar ligand affinities and CAMP 
coupling, but were shown to have tissue specific regulation [ 181. 
The second possibility is that MORlA is heterogeneous nu- 
clear RNA that has been incompletely spliced. This seems un- 
likely, because if heterogeneous nuclear RNA were present 
additional PCR products containing the 0.8 kb intron 2 would 
have been detected in Fig. 1. 
Further studies to detect the MORlA receptor protein and 
to determine the effects of its unique C-terminus will help to 
establish and clarify the role of the MORlA variant. MORlA’s 
Table 1 
Pharmacological characterization of the cloned p opioid receptors 
Lizand MORl MORlA 
Non-selective 
diprenorphine 
& (nW 4 WW & (nM) ill MM) 
0.13 f 0.08 0.13 r 0.07 
p-selective 
DAMGO 
rc-selective 
U69,593 
&selective 
DPDPE 
0.26 f0.06 0.5 to.1 0.15 f0.04 1.0 fO.l 
> 1000 >lOOO 
> 1000 > 1000 
The binding data were collected in triplicate and analyzed with the [22] Munson, P.J. and Rodbard, D. (1980) Anal. Biochem. 107, 22& 
LIGAND program. Data are expressed as + S.E.M. 239. 
Table 2 
Receptor coupling to CAMP activity (inhibition) 
Receptor MORl MORlA 
Control 1.5 f 0.5 2.0 + 0.5 
+ Forskolin 24 + 2.5 25 + 1.5 
+ Forskolin 
+ 0.5 mM DAMGG 16 + 1.6 15 f 1.0 
% inhibition 32 39 
Synthesis of CAMP @mol/S x 105) in stable cell lines expressing the 
receptor cDNAs. Data are expressed as f S.E.M. 
unique C-terminus could have effects on G-protein coupling or 
on tissue distribution. It could also be involved in determining 
whether the receptor is localized to specific regions of the neu- 
ron. In addition, the high homology between human and rat 
,u opioid receptors uggests that MORlA may be found in rat 
brain, where regional brain distributions can be more easily 
determined. 
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